RxDoctor Payments Data

Erin Lagroue, NP

Family · Walker, LANPI 1538471495

Payments from drug & device makers

$11,301in general payments, 2019–2025

Across 673 payments — averaging $16.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • GSK$1K
  • Novo Nordisk$1K
  • Lilly USA, LLC$1K
  • Pfizer$851
  • Bayer$804
  • plus $5K from 42 others

What the payments were for

  • Food & beverage$11,301100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,301 in reported general payments places this provider in the 95th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Medicare billing

Part B allowed, 2024
$37,453
Medicare patients
110
Services billed
490

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide152$185,682
MounjaroTirzepatide141$180,860
JardianceEmpagliflozin110$118,567
TrulicityDulaglutide61$95,661
LinzessLinaclotide49$52,514
EliquisApixaban52$37,838
Soliqua 100-33Insulin Glargine/Lixisenatide38$35,738
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$29,214
UbrelvyUbrogepant22$28,066
FarxigaDapagliflozin Propanediol28$27,321
JanuviaSitagliptin Phosphate25$27,249
XareltoRivaroxaban29$21,252
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog17$20,772
Stiolto RespimatTiotropium Br/Olodaterol Hcl17$20,196
Tresiba Flextouch U-200Insulin Degludec12$18,492

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,005$276,521202 claims
Novo NordiskOzempic$1,037$185,682152 claims
Boehringer IngelheimJardiance, Stiolto Respimat, Synjardy Xr$672$151,312142 claims
AbbVieLinzess, Ubrelvy, Vraylar, Synthroid$1,205$100,407119 claims
PfizerEliquis$851$37,83852 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$298$35,73838 claims
GSKTrelegy Ellipta$1,037$29,21435 claims
AstraZenecaFarxiga$308$27,32128 claims
MerckJanuvia$391$27,24925 claims
Johnson & JohnsonXarelto$201$21,25229 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,610 family providers in Louisiana.

Other family in Walker

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →